Clinical Trial Update: Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating neoadjuvant sunitinib combined with paclitaxel and carboplatin in patients with triple-negative breast cancer completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Sunitinib (sunitinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-12-17